Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

JAMA Netw Open · 2021 · PMC7879233 · PMID 33570575

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP = .09so close (0.05 < p ≤ 0.1)

A greater number of patients had any grade immune-related adverse events in the group with ECOG PS scores of 0 or 1 than in the group with ECOG PS scores of at least 2 (24 [53.3%] vs 9 [31.0%]), but the difference did not reach statistical significance ( P = .09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.